Healthcare stocks in USA
Intrinsic value and value investing analysis for healthcare stocks in USA.
865 companies
Companies
- LLY - Lilly(Eli) & Co: overvalued, -48% margin of safety
- JNJ - Johnson & Johnson: overvalued, -37% margin of safety
- ABBV - Abbvie Inc: overvalued, -175% margin of safety
- MRK - Merck & Co Inc: overvalued, -303% margin of safety
- UNH - Unitedhealth Group Inc: fairly valued, -1% margin of safety
- TMO - Thermo Fisher Scientific Inc: overvalued, -155% margin of safety
- AMGN - AMGEN Inc: overvalued, -27% margin of safety
- GILD - Gilead Sciences Inc: overvalued, -41% margin of safety
- ABT - Abbott Laboratories: overvalued, -53% margin of safety
- PFE - Pfizer Inc: undervalued, +41% margin of safety
- DHR - Danaher Corp: overvalued, -180% margin of safety
- ISRG - Intuitive Surgical Inc: overvalued, -147% margin of safety
- VRTX - Vertex Pharmaceuticals Inc: overvalued, -46% margin of safety
- BMY - Bristol-Myers Squibb Co: undervalued, +50% margin of safety
- MCK - Mckesson Corp: fairly valued, +0% margin of safety
- CVS - CVS Health Corp: slightly overvalued, -14% margin of safety
- SYK - Stryker Corp: overvalued, -42% margin of safety
- HCA - HCA Healthcare Inc: undervalued, +29% margin of safety
- REGN - Regeneron Pharmaceuticals Inc: overvalued, -43% margin of safety
- ELV - Elevance Health Inc: undervalued, +32% margin of safety
- MRNA - Moderna Inc: overvalued, -2999% margin of safety
- CI - Cigna Group: undervalued, +55% margin of safety
- COR - Cencora Inc: overvalued, -27% margin of safety
- BSX - Boston Scientific Corp: undervalued, +33% margin of safety
- NTRA - Natera Inc: overvalued, -613% margin of safety
- CAH - Cardinal Health Inc: overvalued, -34% margin of safety
- BDX - Becton Dickinson & Co: slightly overvalued, -6% margin of safety
- EW - Edwards Lifesciences Corp: overvalued, -117% margin of safety
- VEEV - Veeva Systems Inc: overvalued, -110% margin of safety
- HUM - Humana Inc: slightly overvalued, -16% margin of safety
- A - Agilent Technologies Inc: overvalued, -118% margin of safety
- WAT - Waters Corp: overvalued, -264% margin of safety
- IQV - IQVIA Holdings Inc: overvalued, -47% margin of safety
- IDXX - Idexx Laboratories Inc: overvalued, -121% margin of safety
- MDLN - Medline Inc: not valued
- RVMD - Revolution Medicines Inc: no published value
- RPRX - Royalty Pharma plc: overvalued, -65% margin of safety
- BIIB - Biogen Inc: overvalued, -98% margin of safety
- ILMN - Illumina Inc: overvalued, -264% margin of safety
- GEHC - GE HealthCare Technologies Inc: slightly undervalued, +7% margin of safety
- CNC - Centene Corp: slightly undervalued, +16% margin of safety
- MTD - Mettler-Toledo International Inc: overvalued, -164% margin of safety
- ZTS - Zoetis Inc: undervalued, +30% margin of safety
- RMD - Resmed Inc: slightly undervalued, +7% margin of safety
- DXCM - Dexcom Inc: overvalued, -46% margin of safety
- LH - Labcorp Holdings Inc: overvalued, -75% margin of safety
- WST - West Pharmaceutical Services Inc: overvalued, -243% margin of safety
- DGX - Quest Diagnostics Inc: slightly overvalued, -9% margin of safety
- UTHR - United Therapeutics Corp: fairly valued, +0% margin of safety
- INSM - Insmed Inc: overvalued, -291% margin of safety
- INCY - Incyte Corp: slightly undervalued, +14% margin of safety
- GH - Guardant Health Inc: overvalued, -1043% margin of safety
- ALNY - Alnylam Pharmaceuticals Inc: undervalued, +52% margin of safety
- THC - Tenet Healthcare Corp: undervalued, +51% margin of safety
- VTRS - Viatris Inc: not valued
- MEDP - Medpace Holdings Inc: overvalued, -30% margin of safety
- ZBH - Zimmer Biomet Holdings Inc: undervalued, +37% margin of safety
- RVTY - Revvity Inc: overvalued, -200% margin of safety
- EXEL - Exelixis Inc: slightly undervalued, +16% margin of safety
- CRL - Charles River Laboratories International Inc: overvalued, -675% margin of safety
- HALO - Halozyme Therapeutics Inc: overvalued, -38% margin of safety
- NBIX - Neurocrine Biosciences Inc: undervalued, +27% margin of safety
- BBIO - BridgeBio Pharma Inc: overvalued, -1419% margin of safety
- GKOS - Glaukos Corp: overvalued, -930% margin of safety
- SOLV - Solventum Corp: undervalued, +50% margin of safety
- EHC - Encompass Health Corp: fairly valued, +2% margin of safety
- BTSG - BrightSpring Health Services Inc: overvalued, -97% margin of safety
- TEM - Tempus AI Inc: overvalued, -581% margin of safety
- SMMT - Summit Therapeutics Inc: no published value
- PEN - Penumbra Inc: overvalued, -327% margin of safety
- DVA - DaVita Inc: undervalued, +55% margin of safety
- BAX - Baxter International Inc: overvalued, -404% margin of safety
- ELAN - Elanco Animal Health Inc: overvalued, -52% margin of safety
- TECH - Bio-Techne Corp: overvalued, -213% margin of safety
- BMRN - Biomarin Pharmaceutical Inc: overvalued, -206% margin of safety
- COO - Cooper Companies Inc: fairly valued, +3% margin of safety
- RGEN - Repligen Corp: overvalued, -523% margin of safety
- AVTR - Avantor Inc: overvalued, -330% margin of safety
- MOH - Molina Healthcare Inc: undervalued, +30% margin of safety
- ALGN - Align Technology Inc: overvalued, -37% margin of safety
- ENSG - Ensign Group Inc: fairly valued, -2% margin of safety
- KYMR - Kymera Therapeutics Inc: overvalued, -1387% margin of safety
- GMED - Globus Medical Inc: undervalued, +26% margin of safety
- PODD - Insulet Corp: slightly overvalued, -10% margin of safety
- UHS - Universal Health Services Inc: undervalued, +64% margin of safety
- TWST - Twist Bioscience Corp: overvalued, -438% margin of safety
- BIO - Bio-Rad Laboratories Inc: overvalued, -522% margin of safety
- MDGL - Madrigal Pharmaceuticals Inc: not valued
- KRYS - Krystal Biotech Inc: not valued
- PCVX - Vaxcyte Inc: no published value
- CAI - Caris Life Sciences Inc: not valued
- HSIC - Henry Schein Inc: slightly overvalued, -8% margin of safety
- OSCR - Oscar Health Inc: no reliable verdict
- PTGX - Protagonist Therapeutics Inc: overvalued, -694% margin of safety
- TGTX - TG Therapeutics Inc: slightly overvalued, -12% margin of safety
- HNGE - Hinge Health Inc: not valued
- TXG - 10x Genomics Inc: overvalued, -1979% margin of safety
- SYRE - Spyre Therapeutics Inc: no published value
- IBRX - ImmunityBio Inc: not valued
- CORT - Corcept Therapeutics Inc: overvalued, -635% margin of safety